These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 8513454

  • 1. Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts.
    Siesjö P, Visse E, Lindvall M, Salford L, Sjögren HO.
    Cancer Immunol Immunother; 1993 Jul; 37(1):67-74. PubMed ID: 8513454
    [Abstract] [Full Text] [Related]

  • 2. Increased proportion of CD8+ tumor responsive T cells after immunization with tum- versus tum+ rat glioma.
    Siesjö P, Visse E, Sjögren HO.
    Cell Immunol; 1995 Oct 15; 165(2):225-33. PubMed ID: 7553887
    [Abstract] [Full Text] [Related]

  • 3. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment.
    Siesjö P, Visse E, Sjögren HO.
    J Immunother Emphasis Tumor Immunol; 1996 Sep 15; 19(5):334-45. PubMed ID: 8941873
    [Abstract] [Full Text] [Related]

  • 4. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells.
    Visse E, Siesjö P, Widegren B, Sjögren HO.
    Cancer Gene Ther; 1999 Sep 15; 6(1):37-44. PubMed ID: 10078962
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical analysis of glioma-infiltrating leucocytes after peripheral therapeutic immunization with interferon-gamma-transfected glioma cells.
    Visse E, Johansson AC, Widegren B, Sjögren HO, Siesjö P.
    Cancer Immunol Immunother; 2000 Jun 15; 49(3):142-51. PubMed ID: 10881693
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells.
    Badn W, Hegardt P, Fellert MA, Darabi A, Esbjörnsson M, Smith KE, Janelidze S, Salford LG, Visse E, Siesjö P.
    Scand J Immunol; 2007 Mar 15; 65(3):289-97. PubMed ID: 17309784
    [Abstract] [Full Text] [Related]

  • 7. In situ augmentation of class I major histocompatibility antigen expression on immunogenic variants of a spontaneous murine mammary carcinoma.
    Elliott BE, Carlow DA, Ivimey L, Arnold M, Hampton N, Bosman P.
    Cancer Res; 1987 Sep 15; 47(18):4915-23. PubMed ID: 2441856
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Postimmunization with IFN-gamma-secreting glioma cells combined with the inducible nitric oxide synthase inhibitor mercaptoethylguanidine prolongs survival of rats with intracerebral tumors.
    Badn W, Visse E, Darabi A, Smith KE, Salford LG, Siesjö P.
    J Immunol; 2007 Sep 15; 179(6):4231-8. PubMed ID: 17785863
    [Abstract] [Full Text] [Related]

  • 11. A model for evaluating therapeutic response of combined cancer treatment modalities: applied to treatment of subcutaneously implanted brain tumors (N32 and N29) in Fischer rats with pulsed electric fields (PEF) and 60Co-gamma radiation (RT).
    Persson BR, Bauréus Koch C, Grafstrom G, Engstrom PE, Salford LG.
    Technol Cancer Res Treat; 2003 Oct 15; 2(5):459-70. PubMed ID: 14529312
    [Abstract] [Full Text] [Related]

  • 12. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
    Soos JM, Krieger JI, Stüve O, King CL, Patarroyo JC, Aldape K, Wosik K, Slavin AJ, Nelson PA, Antel JP, Zamvil SS.
    Glia; 2001 Dec 15; 36(3):391-405. PubMed ID: 11746775
    [Abstract] [Full Text] [Related]

  • 13. Modified immunoregulation associated with interferon-gamma treatment of rat glioma.
    Oshiro S, Liu Y, Fukushima T, Asotra K, Black KL.
    Neurol Res; 2001 Jun 15; 23(4):359-66. PubMed ID: 11428516
    [Abstract] [Full Text] [Related]

  • 14. Increase in H-2 antigen expression and immunogenicity of BL6 melanoma cells treated with N-methyl-N'-nitronitrosoguanidine.
    Gorelik E, Peppoloni S, Overton R, Herberman RB.
    Cancer Res; 1985 Nov 15; 45(11 Pt 1):5341-7. PubMed ID: 2413992
    [Abstract] [Full Text] [Related]

  • 15. Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy.
    Wen PY, Lampson MA, Lampson LA.
    J Neuroimmunol; 1992 Jan 15; 36(1):57-68. PubMed ID: 1735769
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro.
    Akbasak A, Oldfield EH, Saris SC.
    J Neurosurg; 1991 Dec 15; 75(6):922-9. PubMed ID: 1941122
    [Abstract] [Full Text] [Related]

  • 18. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma.
    Smith KE, Janelidze S, Visse E, Badn W, Salford L, Siesjö P, Darabi A.
    Int J Cancer; 2007 Jan 01; 120(1):75-80. PubMed ID: 17044023
    [Abstract] [Full Text] [Related]

  • 19. The induction of enhanced antitumor effect against a nonimmunogenic tumor by highly immunogenic variants obtained by mutagen treatment.
    Sainouchi R, Terata N, Kodama M.
    Jpn J Cancer Res; 1988 Nov 01; 79(11):1247-53. PubMed ID: 3147279
    [Abstract] [Full Text] [Related]

  • 20. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.
    Uyttenhove C, Van Snick J, Boon T.
    J Exp Med; 1980 Nov 01; 152(5):1175-83. PubMed ID: 6776226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.